What is Raymond James’ Forecast for TSE:PRN FY2024 Earnings?

Profound Medical Corp. (TSE:PRN) – Equities researchers at Raymond James increased their FY2024 earnings estimates for Profound Medical in a research report issued to clients and investors on Wednesday, December 11th. Raymond James analyst M. Freeman now forecasts that the company will post earnings of ($1.79) per share for the year, up from their prior forecast of ($1.82). Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical’s Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($1.24) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at $1.50 EPS and FY2028 earnings at $3.43 EPS.

Profound Medical Stock Up 0.5 %

Shares of PRN stock opened at C$10.28 on Monday. The company has a 50 day simple moving average of C$10.81 and a two-hundred day simple moving average of C$11.60. The stock has a market cap of C$251.65 million, a P/E ratio of -6.17 and a beta of 0.81. Profound Medical has a 12 month low of C$9.55 and a 12 month high of C$15.75. The company has a current ratio of 8.61, a quick ratio of 14.98 and a debt-to-equity ratio of 16.95.

Insiders Place Their Bets

In other Profound Medical news, Senior Officer Thomas Michael Tamberrino purchased 13,333 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were bought at an average price of C$10.65 per share, with a total value of C$141,996.45. Also, Director Arun Menawat Dr. acquired 20,000 shares of Profound Medical stock in a transaction that occurred on Tuesday, December 10th. The stock was purchased at an average cost of C$10.65 per share, for a total transaction of C$213,000.00. Company insiders own 8.62% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.